Clinical trial · Interventional
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
Minimizing Fatigue and Inflammation in Survivors of Cancer: A Pilot Randomized Clinical Trial of the Seaweed Supplement Fucoidan
NCT06295588CI-TRIAL-00097997active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue | — | UNRESOLVED | — |
| Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fucoidan extracted from F. Vesiculosus | Drug | — | UNRESOLVED |
| Fucoidan extracted from U. Pinnatifida | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Fucoidan
- description
- They will receive 4 grams daily of fucoidan extracted from F. Vesiculosus for 8 weeks.
- interventionNames
- Drug: Fucoidan extracted from F. Vesiculosus
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- They will receive usual care for 8 weeks followed by 4 grams daily of fucoidan extracted from U. Pinnatifida for 8 weeks.
- interventionNames
- Drug: Fucoidan extracted from U. Pinnatifida
Primary outcomes (3)
- measure
- percentage of participants who are randomized to the study out of all participants approached
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Survivors of cancer * Age 18 or older * Speak and understand English * Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) ≤10 years prior to enrollment. * Have a baseline level of fatigue, as determined by reporting a score of 4 or higher for the question, "In the last week, how bad was your worst fatigue on a scale from 0-10?" * Be willing to commit to the fucoidan supplement dosing and delivery method, to complete evaluation instruments, and to attend all study visits. * Completed Informed Consent Exclusion Criteria: * Current warfarin or other anti-coagulation medication use. * Current use of supplements that contain fucoidan * Any allergy to fucoidan * Be diagnosed with a major psychiatric illness requiring hospitalization within the last year. * Be diagnosed with dementia. * Be pregnant or nursing
References
Publications (0)
Data not yet available
No reference posted for this study.